Nanobiotix Reports Strong 2025 Financial Turnaround & Key Clinical Progress

summarizeSummary

Nanobiotix S.A. filed its comprehensive 20-F annual report for 2025, detailing a significant reduction in net loss, a major revenue increase, and securing substantial non-dilutive financing, alongside positive clinical trial advancements for its lead product candidate JNJ-1900 (NBTXR3).

check_boxKey Events

• Significant Financial Improvement

  Nanobiotix reported a 65% reduction in net loss for 2025, narrowing to €24.0 million from €68.1 million in 2024. Total revenues and other income swung to a positive €32.6 million in 2025, compared to a negative €7.2 million in 2024, primarily due to a €21.8 million positive impact from a Janssen agreement amendment.

• Major Non-Dilutive Royalty Financing Secured

  The company entered into a royalty financing agreement with HCRx for up to $71 million, receiving an initial $50 million upfront payment in December 2025. This non-dilutive capital infusion significantly strengthens the company's liquidity.

• Janssen Partnership Restructuring

  An amendment to the global licensing agreement with Janssen in March 2025 transferred almost all financial responsibility for the pivotal Phase 3 NANORAY-312 trial to Janssen, reducing Nanobiotix's future R&D obligations. The total potential deal value was adjusted from $2.7 billion to $2.6 billion.

• Positive Clinical Trial Advancements

  The report highlights promising initial Phase 2 clinical trial data for CONVERGE (NSCLC) with a 71.4% Objective Response Rate, final positive data for the Phase 1 Study 102 (LA-HNSCC) with a median Overall Survival of 23.1 months, and continued progress in other oncology indications for JNJ-1900 (NBTXR3).

auto_awesomeAnalysis

This 20-F annual report details a significant positive shift in Nanobiotix's financial health and provides comprehensive updates on its critical product pipeline. The substantial reduction in net loss and the swing to positive revenue for 2025, driven by a key amendment to the Janssen agreement, indicate improved financial stability. The new non-dilutive royalty financing further strengthens the company's cash position, extending its operational runway. Multiple positive clinical trial updates across various oncology indications for JNJ-1900 (NBTXR3) reinforce the product's potential and de-risk its development pathway. The confirmation of no substantial doubt about the company's going concern status and achievement of Sarbanes-Oxley Section 404(b) compliance are additional positive signals for investors, demonstrating robust governance and operational control. This comprehensive report paints a picture of a company making significant strides in both its financial management and core therapeutic development.